Affomix to Provide Antibodies for Kalgene’s Therapeutic and Companion Diagnostics Program
News Dec 30, 2009
Affomix Corporation has announced that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer.
Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics. The company's portfolio of oncology products is at various stages in development, from assay development to advanced clinical trials.
“After much diligence, Kalgene chose Affomix as the company to rapidly procure antibodies against our proprietary targets”
Under the terms of the agreement Affomix will generate antibodies against several proprietary targets selected by Kalgene. Affomix will utilize its Y2HExpress™ technology for the selection of single-chain antibodies with substantially increased throughput, and specificity, over conventional Y2H and alternative antibody selection methodologies.
Financial terms of the service agreement were not disclosed, nor were the financial milestones related to diagnostic and therapeutic applications.
“After much diligence, Kalgene chose Affomix as the company to rapidly procure antibodies against our proprietary targets”, said Dr. T. Nathan Yoganathan, President and CEO of Kalgene Pharmaceuticals Inc. “Y2HExpress™ has the ability to select antibodies at an unprecedented level of specificity, combined with very favorable financial advantages,” Yoganathan continued.
“The application of Affomix technology will accelerate our product development schedule”, said Robert Davidson, Director of Science and Technology for Kalgene.